Moxifloxacin Anfarm (Moxifloxacin)

Moxifloxacin blocks bacterial DNA gyrase and topoisomerase IV, enzymes required for DNA replication and transcription. By binding to these enzymes, it prevents DNA supercoiling, halting bacterial cell division and leading to bacterial death. This mechanism provides bactericidal activity across many common pathogens.

The specific dose and duration of Moxifloxacin Anfarm are determined by the prescribing clinician based on the infection type, severity, patient weight, renal and hepatic function, and local guidelines. Healthcare professionals should follow the approved prescribing information and adjust as clinically indicated.

Safety data for Moxifloxacin Anfarm in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians must evaluate each case individually and consider alternative therapies when possible.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain if needed), and required import documentation.

Moxifloxacin offers a broader spectrum against atypical pathogens and has enhanced activity against Gram‑positive organisms compared with older fluoroquinolones like ciprofloxacin. It also provides once‑daily dosing for many indications, which can improve adherence. However, safety considerations such as QT prolongation and tendon toxicity remain similar across the class.

Moxifloxacin Anfarm should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. Do not store at room temperature for extended periods, as stability may be compromised.

Moxifloxacin Anfarm is administered intravenously by a healthcare professional. The infusion is typically given over a set period as directed by the prescriber, using aseptic technique and appropriate IV equipment. Administration details, including infusion rate and dilution, are outlined in the product’s prescribing information.

Serious risks include tendon rupture (especially the Achilles tendon), QT interval prolongation leading to cardiac arrhythmias, severe hypersensitivity reactions such as Stevens‑Johnson syndrome, Clostridioides difficile‑associated colitis, and potential hepatotoxicity. Patients should be monitored closely for these events, and therapy should be discontinued if they occur.

Moxifloxacin Anfarm is contraindicated in patients with a known hypersensitivity to moxifloxacin or other fluoroquinolones. Caution is advised for individuals with a history of tendon disorders, prolonged QT interval, uncontrolled epilepsy, or those receiving concurrent corticosteroids. Pregnant or breastfeeding women should only use it when clearly indicated and after risk‑benefit assessment.